AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 42 min read$INSP

Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance?

Inspire Medical Systems (INSP) reported Q2 2026 adjusted EPS of $0.14, beating estimates, and raised its 2026 revenue and earnings guidance. Despite U.S. coding and reimbursement challenges, international revenues supported the revised outlook. The stock has seen volatility, with a 50.86% 90-day return but a 32.65% YTD decline. Analysts' price targets range from $40 to $85, with a consensus of $60.40, suggesting a 3% overvaluation.

Original reporting
simplywall.st
Published Sep 4, 2026, 5:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 2:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance? — source image
Source · simplywall.st
Decision brief

The 30-second read

$INSPBullishMed
01

Why it matters

The earnings beat and guidance raise short‑term sentiment but long‑term risk remains due to reimbursement issues.

02

Market read

Earnings surprise and guidance update are the primary drivers of relevance for this small‑cap health‑tech stock.

03

What to watch

International revenue contribution and potential future regulatory changes.

Relevance 7/10Novelty 7/10Timing: post‑quarter earnings release

Background

Simply Wall St provides a valuation narrative and price target range for Inspire Medical Systems.

Company-level read

Ticker impact

$INSPBullishMedium confidence
Context

Q2 2026 adjusted EPS of $0.14 beat expectations and management raised 2026 revenue and earnings guidance.

Expected impact

Potential modest price rally on the news, but volatility likely persists.

Evidence & confidence

Guidance lift is new information, yet the company faces coding/reimbursement risks that cap upside.

Market effects

Sector

Highlights ongoing reimbursement challenges for med‑tech firms, may affect peer valuations.

Regional

U.S. med‑tech sector sentiment could see slight lift.

Global

Limited to investors tracking small‑cap healthcare equities.

Counterpoint

What could challenge this read

Higher guidance may be overly optimistic given persistent coding uncertainties.

Key entities

  • company
    Inspire Medical Systems

    Medical device maker reporting Q2 2026 results.

Read at source← All news

Related articles

OCT 4
$INSPMed

Inspire Medical (INSP): How Much Optimism Is Baked Into This Medtech Stock?

Inspire Medical Systems (INSP) reported a 7.6% revenue decline to $200.6M in Q2, with US sales driving the drop. Despite this, the company boasts an 85.5% gross margin, $415.2M in cash, and raised 2026 revenue guidance to $835M-$875M. The AMA approved new billing codes for its Inspire V system, a key reimbursement milestone. However, the stock trades at a high forward P/E of 59.17, reflecting investor optimism about future earnings.

insidermonkey.com3 min
OCT 2
$INSPMedAI 8/10

Inspire Secures AMA Approval For New Hypoglossal Nerve Stimulation Codes

Inspire Medical Systems (INSP) received AMA approval for new CPT codes covering hypoglossal nerve stimulation procedures, including its Inspire V system. The codes, effective January 1, 2028, aim to simplify reimbursement and expand patient access. CMS will determine reimbursement values, with proposed valuations expected in July 2027. INSP stock closed at $70.78, up 2.05%.

rttnews.com1 min
OCT 1
$INSPMedAI 8/10

Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel

Inspire Medical Systems (INSP) announced the AMA approved new CPT codes for its Inspire V system, effective January 1, 2028. The company expects this to streamline reimbursement and expand patient access. CMS will determine Medicare payments for the new codes, with proposed valuations expected in July 2027 and final valuations in November 2027.

globenewswire.com2 min
SEP 11
$INSPHigh

Why Inspire Medical Systems (INSP) Stock Is Up Today

Inspire Medical Systems (INSP) stock rose 7.4% after Stifel raised its price target to $80.00, citing positive sentiment. Shares later cooled to $70.71, up 3.8%. The company's shares are volatile, with significant moves tied to regulatory changes and analyst upgrades. INSP is down 23.4% YTD and 50.9% off its 52-week high.

financialcontent.com2 min
AUG 14
$INSPMedAI 8/10

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems (NYSE:INSP) reported Q2 2026 revenue of $200.6M, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Gross margin rose to 85.5%. Full-year revenue guidance was raised to $835M-$875M, with an estimated $40M Q2 and $120M-$130M full-year reimbursement headwind.

aol.com7 min